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Epidemiology
● COVID morbidity and mortality disproportionate falls on those who are of racial/ethnic minorities for both
obvious and entirely preventable reasons. A new study has pushed further analyses, identifying the social
determinates of poverty, incomplete high-school, and veterans as additional risk factors.
● Prioritizing COVID-19 took attention away from more standard hospital infection control practices, driving
an uptick in multi-drug resistant and device-associate infections.
● Regarding healthcare workers in New Jersey, phlebotomists, environmental services, and food services, were
at highest risk for COVID infection, not doctors or nurses.
● January 22 data show DC Hospitals are at 87% ICU capacity. Hospitals are at 86% capacity.
The New Variants
● There are currently at least 3 new strains, the UK, South African and Brazilian Variants. Most experts believe
that antigenic drift in the spike protein should still be neutralized by vaccines and antibodies. However,
researchers in South Africa and Brazil are more concerned.
Testing
● Home specimen collection tests trickle out. Labcorp and Quest both have versions of at home collection kits.
Patients can go to LabCorp’s website and fill out a form for the Pixel Home Test. It’s a nasal PCR that comes
with a pre-packaged FedEx return envelope. Turn-around time limiting factor: shipping.
● PCR positivity peaks within the first 3 days of symptom onset. By day 7, only 19.3% of patients had positive
IgM titers while 44% were IgG positive. By week 4, 93% of positive patients had IgG positivity. While IgM
titers may be more associated with severity, IgG titers might be a better indicator for infection (due to a likely
window period). 27% of patients were still PCR positive at 4 weeks.
● A study of quarantined college athletes found that test positivity peaks at 5 days following exposure. At 5
days, 27 % of exposures tested positive, decreasing to <5% after day 10. Practically, this may lend credence to
exposure testing on day 5, and support a shorter, 10 day quarantine.
● Nasal v salivary swabs. In a large meta-analysis, Nasal swabs showed 1.5-7.9% greater sensitivity.
● The presence of certain auto-immune diseases, especially RA and SLE, may cause false positives in
serological COVID testing.
● A meta-analysis indicates elevated procalcitonin, LDH, CRP, D-dimer, tPa levels, and decreased albumin are
all indicators of disease severity. While thresholds are yet to be determined, these markers may prove useful
for disposition.
Pediatrics
● Hospitalization rates among children are increasing. Of note, its seems like the states with the most laissezfaire approaches to public health are seeing the highest spikes in pediatric admissions.
Therapeutics
● The NHS has put out an interim recommendation based on research from an ongoing international,
multifactorial, adaptive platform trial: ICU patients treated with IL-6 inhibitors plus corticosteroids and
remdesivir, saw a 24% reduction in fatality, and 7 fewer ventilator days.
● Anakinra, the IL-1 inhibitor shows promise for mortality reduction, in very small studies.
● In the perpetual debate on coagulopathy, this Danish nation-wide population-based study suggests COVID
patients are not actually at increased risk for VTE or bleeding, compared to other hospitalized patients.

● Despite the 6mg of dexamethasone per day, recommended by the RECOVERY Trial - timing, dosing, and
efficacy are still being debated.
● The Montreal Heart Institute is releasing preliminary results of a double-blind prospective cohort study of
4000 patients, suggesting that colchicine may reduce the risk of hospitalization by 25% and fatality by 44%.
These findings could be important but must be viewed as preliminary since the study has not been published
in a peer reviewed journal.
The Biden Plan – This may affect GW’s roll-out
18 million shots given, and 36 million doses have been distributed. The Biden Administration has proposed:
● $20 billion for increased vaccination efforts, including 100 FEMA-ran vaccine centers, expanded community
vaccine centers including in schools & stadiums, 100,000 more public health workers, and advertisements.
● $50 billion for increased testing,
● $40 billion more for supplies including syringes and PPE.
● Defense Production Act to ensure supply-chain adequacy.
● While phase 1 includes nursing home population and healthcare workers, Biden proposes phase 2 to include
everyone >65 and essential workers including teachers and grocers.
● This will be led by Dr David Kessler, pediatrician and ex-FDA commissioner.
Given the slow roll out, many, including the Biden administration have advocated for releasing all available doses.
The data: At 2 weeks, a single Pfizer dose is somewhere between 50-82% effective. At 4 weeks, a single Moderna
dose was up to 80.2% effective. The assumption: Our vaccine supply chain is adequate, and there’s no obvious reason
to expect disruptions. The calculus: A delayed second dose (even up to 12 weeks) should still have the boosting effect
on immunity, and with scaling manufacturing, we may not even be delayed. Some propose that good efficacy for
more people now is better than amazing efficacy later. This approach has been recommended by the NHS’s advisory
panel. This is by no means settled.
Vaccines – the old and the new
 DC has moved into the next stage of vaccine distribution – adults > 65 targeting vulnerable zip codes first.
Likewise MD and VA have their own strategies. Patients can sign up online.
 Only 29 cases of anaphylaxis have been reported for the Pfizer and Moderna Vaccines, at a rate of 5.5/1mill
people. Mostly in people with pre-existing severe allergies. By comparison, 6.6/1 million people die from
covid, daily (2000/day).
 The Oxford vaccine (previously known as AstraZenica, but all the bench work was actually done by
academics), has some yet-to-be-explained paradoxical results. Early analysis suggests that a half-dose followed
by a full-dose booster was 90% effective in preventing COVID-19, while 2 full doses were only 62% effective.
While acknowledging the need for investigation, an interim analysis estimates 70% efficacy after 2 doses. The
advantage is that super cold chain is not required.
 Johnson & Johnson/HHS is in phase 3 of a single-dose vaccine that can survive for 3 months at 2-8c showing
90% efficacy by day 29.
 We are currently injecting ~900,000 doses of vaccine per day. There are 260,000,000 eligible adults (requiring
~520,000,000 doses, children aren’t approved yet). That math is not encouraging, but supply is increasing
every week. Pfizer and Moderna combined have promised 400 million doses by summer. If Oxford, and
Johnson & Johnson, and Novovax are approved, outlooks improve (there are still some 17 vaccines in stage 2
trials). Accordingly, projections range from normalcy this spring (multiple vaccines approved, supply
continues to increase, vaccine trucks aren’t being hijacked), to early 2022 (supply does not increase, no other
vaccines are approved, SSRI’s sell out).
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